Navigation Links
CeNeRx BioPharma Completes $13 Million Series C Financing
Date:8/13/2010

RESEARCH TRIANGLE PARK, N.C., Aug. 13 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing.  Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing.  CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.

"These funds will support the Phase II trial of TriRima as monotherapy for treatment-resistant depression," said Barry Brand, Chief Executive Officer of CeNeRx.  "We are pleased with the continuing confidence and support of our investors and look forward to advancing the CeNeRx pipeline."

CeNeRx is preparing to conduct a Phase II trial with an improved formulation of its lead product candidate TriRima for treatment-resistant depression.  TriRima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A).  The triple action mechanism of TriRima elevates the levels of three key neurotransmitters that positively affect mood and anxiety, compared to the one or two neurotransmitters addressed by most current antidepressant drugs.  This triple action mechanism may benefit patients not responding to traditional single or dual action products, while the selectivity and reversibility of TriRima are expected to eliminate or reduce the risk of food-associated cardiovascular side effects of conventional MAO inhibitors.

About CeNeRx BioPharma

CeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system.  CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment-resistant depression.  RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile.  The company's CNS pipeline also includes clinical-stage hypothalamic-pituitary adrenal (HPA) axis modulators for the treatment of a variety of CNS disorders including anxiety and depression; a small molecule, orally active agent for the prevention and treatment of neuropathies and neurodegenerative disorders; and a series of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity.  More information about CeNeRx can be found at www.cenerx.com.

Contact:

GendeLLindheim BioCom Partners

Barbara Lindheim

212 918 4650




'/>"/>
SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
2. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
3. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Almac Launch Biomarkers for Biopharma
6. Health Outcomes Data Essential to Biopharmaceutical Sales Process
7. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
8. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
9. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
10. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
11. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- Patients in Alabama seeking prostate care ... longer have to travel out of state. Vituro Health ... Centers of Alabama to provide a total prostate management ... Alabama is known throughout ... cancer using many different modalities. They are the largest and ...
(Date:2/5/2016)... 5, 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ... CEO, will be presenting at Source Capital Group,s 2016 Disruptive ... at 2:15 p.m. ET on Wednesday, February 10, ... discussion taking place at 3:15 p.m. ET. http://www.aethlonmedical.com ... hour after the conclusion of the live event. The panel ...
(Date:2/5/2016)... BEIJING , Feb. 5, 2016 ... ("Dehaier Medical" or the "Company"), which develops, markets ... products in China and ... restructuring plan which aims to concentrate the Company,s ... wearable sleep respiratory business and to focus more ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that ... the event they are experiencing an illness. Migraines are a severe form of a ... with migraines would not wish the pain on their worst enemy, the feeling can ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... Care for Patients with Rare Diseases, a continuing medical education (CME) event presented ... the first of its kind—and a first for ACCORD, whose mission is to ...
(Date:2/5/2016)... ... 2016 , ... KICVentures ( http://www.kicventures.com ) announced today that ... York City on Thursday, January 21, 2016. Kingsley R. Chin, the CEO ... the varsity Columbia soccer program) spoke at the event, offering professional insight based ...
(Date:2/5/2016)... ... February 05, 2016 , ... Susan Polk Health Insurance Company ... users can expect to see in 2016. To view the report, see below, or ... directly impact many San Luis Obispo seniors who rely on Medicare health insurance and ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis and 30 ... 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 Conference "It's ... speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis (topics and ...
Breaking Medicine News(10 mins):